Valneva Austria GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$50.1M
Doctors Paid
79
Transactions
2,183
2024 Total
$1.6M
Payment Breakdown by Category
Research$49.9M (99.6%)
Consulting$137,094 (0.3%)
Travel$23,734 (0.0%)
Food & Beverage$2,517 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49.9M | 2,066 | 99.6% |
| Consulting Fee | $137,094 | 56 | 0.3% |
| Honoraria | $45,728 | 19 | 0.1% |
| Travel and Lodging | $23,734 | 24 | 0.0% |
| Food and Beverage | $2,517 | 18 | 0.0% |
Payments by Type
Research
$49.9M
2,066 transactions
General
$209,072
117 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | $28.8M | 42 | 781 |
| IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | $3.8M | 1 | 110 |
| A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | $3.0M | 0 | 123 |
| SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION. | $2.6M | 0 | 77 |
| ALTERNATIVE SCHEDULE STUDY FOR VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY | $1.8M | 0 | 71 |
| A randomized, oberserver-blinded, dose-escalation phase 1 study to assess the safety and immunogenicity of three different dose levels of a live-attenuated Chikungunya virus vaccine candidate (VLA1553) in healthy volunteers aged 18 to 45 years | $1.7M | 0 | 20 |
| IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY | $1.4M | 0 | 22 |
| AN OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE ANTIBODY PERSISTENCE AND LONG TERM SAFETY OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | $1.4M | 11 | 166 |
| ALTERNATIVE SCHEDULE STUDY FOR VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY. | $1.1M | 0 | 25 |
| Randomized Double-Blinded Pilot Study Confirming A Human Challenge Model Using LSN03-016011/A Expressing LT and CS17 and Investigating the Safety of VLA1701 (an Investigational Oral Cholera and ETEC Vaccine) | $683,210 | 0 | 6 |
| A PHASE 1 DOUBLE-BLIND, RANDOMIZED, DOSE-FINDING CLINICAL TRIAL WITH AN OPEN-LABEL RUN-IN PART TO ASSESS THE SAFETY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED WHOLE ZIKA VIRUS VACCINE CANDIDATE (VLA1601) IN HEALTHY FLAVIVIRUS-NAÏVE ADULTS AGED 18 TO 49 YEARS | $616,661 | 0 | 469 |
| SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION. | $496,975 | 10 | 51 |
| A RANDOMIZED, DOUBLE-BLINDED PHASE 3 STUDY TO DEMONSTRATE LOT-TO-LOT CONSISTENCY OF THREE LOTS OF A LIVE-ATTENUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN HEALTHY ADULTS AGED 18 TO 45 YEARS | $475,227 | 12 | 48 |
| Study assessing the Safety and Immunogenicity of two different dose levels of an alum adjuvanted inactivated whole Zika virus vaccine candidate (VLA1601) in healthy flavivirus-naive adults aged 18 to 49 years | $440,746 | 0 | 7 |
| A PHASE 1 DOUBLE-BLIND, RANDOMIZED, DOSE FINDING CLINICAL TRIAL WITH AN OPEN-LABEL RUN-IN PART TO ASSESS THE SAFETY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED WHOLE ZIKA VIRUS VACCINE CANDIDATE (VLA1601) IN HEALTHY FLAVIVIRUS-NAÏVE ADULTS AGED 18 TO 49 YEARS | $369,028 | 0 | 10 |
| Study assessing the vaccina efficacy of VLA1701 against LT-Producing ETEC in a human challenge Model using LSN03-016011/A expressing LT and CS17 | $341,605 | 0 | 3 |
| Study assessing the Safety, Immunogenicity and dose response of VLA15, a new multivalent recombinant OspA vaccine candidate against Lyme Borreliosis, in healthy adults aged below 40 years | $248,339 | 0 | 16 |
| SAFETY AND IMMUNOGENICITY STUDY OF VLA15 A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS A RANDOMIZED, CONTROLLED OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY | $232,192 | 0 | 21 |
| "Study Assessing the Vaccine Efficacy Of VLAl70l Against L'I'-Producing ETEC 1/1A HUIIIII/l Challenge Mode/ Using LSN03-0l6011/A Expressing LT And CSl7" | $113,868 | 0 | 1 |
| Alternative schedule study for VLA15, a MULTIVALENT recombinant OspA BASED vaccine CANDIDATE against Lyme borreliosis, IN HEALTHY ADULTS AGED 18 to 65 years - a Randomized, controlled, observer-blind phase 2 study. | $91,369 | 5 | 18 |
| Live-attenuated Chikungunya (CHIVK) Vaccine (VLA1553) | $53,115 | 0 | 7 |
| SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY | $52,507 | 0 | 2 |
| Live-attenuated Chikungunya (CHIKV) vaccine (VLA1553) | $35,195 | 0 | 7 |
| SAFETY AND IMMUNOGENICITY STUDY OF nVLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY | $26,043 | 0 | 1 |
| VLA84-201 DOSE-CONFIRMATION, IMMUNOGENICITY AND SAFETY STUDY OF THE CLOSTRIDIUM DIFFICILE VACCINE CANDIDATE VLA84 IN HEALTHY ADULTS AGED 50 YEARS AND OLDER. RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE II STUDY | $14,897 | 0 | 1 |
| SAFETY AND IMMUNOGENICITY STUDY OF VLA15 A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS A RANDOMIZED, CONTROLLED OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDYOF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY | $13,490 | 0 | 2 |
| SAFETY AND IMMUNOGENICITY STUDY OFVLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY | $5,225 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Family Medicine | $2.4M | 22 | $109,369 |
| Internal Medicine | $1.5M | 15 | $97,796 |
| Emergency Medicine | $510,921 | 4 | $127,730 |
| Pediatrics | $254,511 | 6 | $42,418 |
| Infectious Disease | $203,133 | 10 | $20,313 |
| Specialist | $144,813 | 2 | $72,406 |
| Rheumatology | $120,065 | 1 | $120,065 |
| Neurology | $118,697 | 1 | $118,697 |
| Clinical & Laboratory Immunology | $83,301 | 2 | $41,651 |
| Obstetrics & Gynecology | $71,628 | 1 | $71,628 |
| Endocrinology, Diabetes & Metabolism | $61,690 | 1 | $61,690 |
| Gynecology | $40,005 | 1 | $40,005 |
| Hospitalist | $33,183 | 1 | $33,183 |
| Clinical Pharmacology | $29,096 | 1 | $29,096 |
| Diagnostic Radiology | $18,409 | 1 | $18,409 |
| Adolescent Medicine | $18,215 | 1 | $18,215 |
| Allergy & Immunology | $16,260 | 2 | $8,130 |
| Pulmonary Disease | $12,473 | 1 | $12,473 |
| Geriatric Medicine | $7,031 | 1 | $7,031 |
| Pediatric Infectious Diseases | $4,928 | 1 | $4,928 |
| Student in an Organized Health Care Education/Training Program | $4,800 | 1 | $4,800 |
| Gastroenterology | $3,539 | 1 | $3,539 |
| Family | $2,512 | 1 | $2,512 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Matthew Davis, Md, MD | Family Medicine | Rochester, NY | $503,424 | $0 |
| Joseph Newberg, Md, MD | Emergency Medicine | La Porte, IN | $371,590 | $0 |
| Suchet Patel, Md, MD | Family Medicine | Endwell, NY | $230,297 | $0 |
| Murray Kimmel, D.o, D.O | Family Medicine | Melbourne, FL | $226,815 | $0 |
| Barbara Rizzardi, Md, MD | Internal Medicine | Sandy, UT | $225,456 | $0 |
| Maria Bermudez, M.d, M.D | Internal Medicine | Pembroke Pines, FL | $209,648 | $0 |
| Gilbert Jenouri, M.d, M.D | Internal Medicine | Milwaukee, WI | $204,592 | $0 |
| Ernie Riffer, Md, MD | Internal Medicine | Phoenix, AZ | $203,736 | $0 |
| Mark Adams, M.d, M.D | Internal Medicine | London, KY | $182,271 | $0 |
| Dr. Patrick Yassini, M.d, M.D | Family Medicine | Coronado, CA | $169,098 | $0 |
| Dr. Brandon Essink, M.d, M.D | Family Medicine | Creighton, NE | $164,933 | $0 |
| Paul Nugent, D.o, D.O | Family Medicine | Cincinnati, OH | $153,373 | $0 |
| Dr. William Smith, M.d, M.D | Specialist | New Orleans, LA | $130,845 | $0 |
| Dr. Lorrie Mcgill, Md, MD | Family Medicine | Papillion, NE | $126,090 | $0 |
| Cory Anderson, Md, MD | Family Medicine | Mesa, AZ | $125,067 | $0 |
| John Ervin, Md, MD | Rheumatology | Kansas City, MO | $120,065 | $0 |
| Dr. Beth Safirstein | Neurology | Hallandale Beach, FL | $118,697 | $0 |
| Dr. Sinikka Green, Md, MD | Emergency Medicine | Austin, TX | $114,945 | $0 |
| Dr. Michael Jacobs, M.d., Ph.d, M.D., PH.D | Internal Medicine | Las Vegas, NV | $109,211 | $0 |
| Dr. Giancarlo Guido, M.d, M.D | Pediatrics | Bronx, NY | $106,768 | $0 |
| Michael Koren, M.d, M.D | Infectious Disease | Silver Spring, MD | $104,453 | $0 |
| Dr. Derek Lewis, M.d, M.D | Family Medicine | Little Rock, AR | $100,957 | $0 |
| Dr. Robert Bell, M.d, M.D | Pediatrics | Beaumont, TX | $98,168 | $0 |
| Kimberly Ellis-Garris, Md, MD | Family Medicine | Fort Sam Houston, TX | $89,641 | $0 |
| Kenneth Dardick, Md, MD | Family Medicine | Storrs, CT | $87,094 | $0 |
Ad
Top Products
- Live-attenuated Chikungunya (CHIVK) Vaccine (VLA1553) $53,115
- Live-attenuated Chikungunya (CHIKV) vaccine (VLA1553) $35,195
Associated Products (2)
Payment Categories
- Food & Beverage $2,517
- Consulting $137,094
- Travel & Lodging $23,734
- Research $49.9M
About Valneva Austria GmbH
Valneva Austria GmbH has made $50.1M in payments to 79 healthcare providers, recorded across 2,183 transactions in the CMS Open Payments database. In 2024, the company paid $1.6M. The top product by payment volume is Live-attenuated Chikungunya (CHIVK) Vaccine (VLA1553) ($53,115).
Payments were distributed across 23 medical specialties. The top specialty by payment amount is Family Medicine ($2.4M to 22 doctors).
Payment categories include: Food & Beverage ($2,517), Consulting ($137,094), Research ($49.9M), Travel & Lodging ($23,734).
Valneva Austria GmbH is associated with 2 products in the CMS Open Payments database.